Blood tests for cancer detection
Pro Research Analysisby 
Searched over 200M research papers
Blood-Based Cancer Detection Tests: Overview and Key Technologies
Blood tests for cancer detection, often called liquid biopsies, are rapidly advancing and offer the potential for early, non-invasive cancer screening. These tests analyze biomarkers such as circulating cell-free DNA (cfDNA), DNA methylation patterns, proteins, and other molecules in the blood to detect cancer signals, sometimes even before symptoms appear 1234+5 MORE.
Multi-Cancer Early Detection (MCED) Blood Tests
Sensitivity and Specificity of MCED Tests
MCED tests are designed to detect multiple types of cancer from a single blood sample. Studies show that these tests generally have high specificity (over 96%), meaning they rarely give false positives, but their sensitivity (ability to correctly identify cancer) varies widely depending on the test and cancer type 1234+3 MORE. For example, the Galleri test reported sensitivity ranging from 20.8% to 66.3% and specificity from 98.4% to 99.5%, while CancerSEEK showed sensitivity from 27.1% to 62.3% and specificity from 98.9% to 99.1% 27. Sensitivity is often lower for early-stage cancers compared to later stages .
Detection of Early-Stage and Asymptomatic Cancers
Some blood tests can detect cancer years before conventional diagnosis. The PanSeer test, for instance, identified cancer in 95% of asymptomatic individuals who were later diagnosed, up to four years before standard methods . Other tests, like CancerSEEK and methylation-based assays, have also demonstrated the ability to detect early-stage cancers, including those for which no standard screening exists 23610.
Types of Cancers Detected
MCED tests can screen for a wide range of cancers, including but not limited to lung, breast, colorectal, prostate, ovary, liver, stomach, pancreas, esophagus, kidney, and brain cancers 1234+2 MORE. Some tests, such as CancerSEEK and MOSA, can also help localize the tissue of origin for the detected cancer signal 246.
Single-Cancer Blood Tests: Focus on Colorectal Cancer
Blood-based tests for specific cancers, like colorectal cancer (CRC), have shown high sensitivity and specificity. One recent test using cfDNA methylation markers achieved 95% sensitivity and 91% specificity for CRC, with strong performance even in early-stage disease . These tests may improve screening adherence due to their convenience and non-invasive nature .
Technological Approaches in Blood-Based Cancer Detection
DNA Methylation and Genetic Markers
Many tests use DNA methylation patterns or tumor-specific mutations in cfDNA to detect cancer. These markers are often shared across multiple cancer types, enabling broad screening from a single blood draw 1359.
Multi-Omic and Protein-Based Approaches
Some tests, like MOSA, analyze a wide range of biomolecules, including proteins and immune markers, to improve detection rates, especially for early-stage and pre-cancerous lesions . Combining multiple types of biomarkers can increase the sensitivity and accuracy of cancer detection 24.
Machine Learning and Data Integration
Advanced machine learning models are used to interpret complex biomarker data, improving the ability to distinguish between cancer and non-cancer samples and to predict the tissue of origin 34510.
Clinical Feasibility, Challenges, and Future Directions
Feasibility and Integration into Screening
Studies support the feasibility of integrating blood-based cancer tests into clinical practice, especially for individuals aged 50 and older 17. These tests are generally easy to administer and could be combined with existing diagnostic pathways .
Limitations and Areas for Further Research
While specificity is consistently high, sensitivity—especially for early-stage cancers—remains variable and is influenced by test design and population . There is a need for more research on patient outcomes, potential harms, and the impact on mortality and quality of life 178. Standardized definitions and frameworks for risk assessment and evidence development are also needed as these tests become more widely used .
Conclusion
Blood-based tests for cancer detection are a promising tool for early, non-invasive screening of multiple cancer types. They offer high specificity and the potential to detect cancers before symptoms arise, but sensitivity varies by test and cancer type. Ongoing research and technological improvements are expected to enhance their accuracy and clinical utility, potentially transforming cancer screening and early intervention.
Sources and full results
Most relevant research papers on this topic